Drug Database
Back to search

Netherlands· NL-47387d1244d6

Xromi 100 mg/ml drank

A hydroxycarbamide product containing hydroxycarbamide, registered in Netherlands by Lipomed GmbH. The same ATC class is registered in 16 of our 19 countries.

ATC L01XX05

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedXromi 100 mg/ml drankATCL01XX05REGISTER NO.NL-47387d1244d6PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about hydroxycarbamideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Hydroxycarbamide is registered in 16 of 19 countries.

Countries holding a registration under ATC L01XX05 (hydroxycarbamide), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 10 of them publish a price we can compare per daily dose
Search hydroxycarbamide products by name

Hydroxycarbamide · ATC L01XX05

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of hydroxycarbamide costs, country by country.

Normalised to the WHO defined daily dose (1.4 g), the median price runs from $0.51 in United States to $16.83 in France — a ×33 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Hydroxycarbamide · price per daily dose (1.4 g)

USD · FX 28 Sept 2026

  • FR France$16.83
  • CH Switzerland$2.74
  • IT Italy$1.13
  • US United States$0.51 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
HYDROXYCARBAMIDE
Manufacturer
Lipomed GmbH
Country
Netherlands (NL)
ATC code
L01XX05
ATC class
Hydroxycarbamide
Defined daily dose
1.4 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/19/1366

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

333 interactions on record for hydroxycarbamide.

Graded by severity as the source publishes them — 31 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check hydroxycarbamide against other medicinesHow interaction checks work

Hydroxycarbamide · interactions on record

333 records

  • 31 severe
  • 101 moderate
  • 15 minor
  • 186 info

Most severe, free to view

  • DidanosineJ05AF02severe
  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Hydroxycarbamide in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All hydroxycarbamide products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Ardjaq, Hydroxycarbamid Devatis
  • Belgium · Hydrea
  • Bulgaria · Хидреа
  • Cyprus · Hydreasyn
  • Czechia · Litalir
  • Germany · Ardjaq, Hydroxycarbamid 1 A Pharma
  • Denmark · Hydroxyurea Medac, Oribamide
  • Estonia · Hydrea
  • Spain · Hidroxicarbamida Hikma, Hidroxicarbamida Medac
  • Finland · Hydrea, Hydroxyurea Medac
  • France · Hydrea, Hydroxycarbamide Arrow
  • United Kingdom (Northern Ireland) · Hydrea, Hydroxycarbamide
  • Greece · Hydreasyn
  • Croatia · Litalir, Xybaid
  • Hungary · Hydroxycarbamide Pharmacenter, Litalir
  • Ireland · Hydrea
  • Iceland · Hydroxyurea Medac, Siklos
  • Italy · Idrossicarbamide Aurobindo, Onco Carbide
  • Liechtenstein · Siklos
  • Lithuania · Hydrea
  • Luxembourg · Hydrea, Hydroxycarbamid Devatis
  • Latvia · Hydrea
  • Malta · Hydroxycarbamide Eugia
  • Norway · Hydroxyurea Medac, Oribamide
  • Poland · Hydroxycarbamid Eugia, Hydroxycarbamid Teva
  • Portugal · Hidroxicarbamida Generis, Hidroxicarbamida Hikma
  • Romania · Hydrea
  • Sweden · Hydrea, Hydroxyurea Medac
  • Slovenia · Hidroksisečnina Aptapharma, Litalir
  • Slovakia · Hydroxykarbamid Medac, Xybaid

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/06565d16-a7af-4ba3-b48b-55f75617fba2
GET /v1/drugs/06565d16-a7af-4ba3-b48b-55f75617fba2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Drank",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/xromi-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Hydroxycarbamide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp122659",
  "excipients": [
    "AARDBEIENSMAAKSTOF 11442-81",
    "GLYCEROLTRIACETAAT (E 1518)",
    "METHYLPARAHYDROXYBENZOAAT (E 218)",
    "NATRIUMHYDROXIDE (E 524)",
    "SUCRALOSE (E 955)",
    "TRIETHYLCITRAAT (E 1505)",
    "WATER VOOR INJECTIE",
    "WATER, GEZUIVERD",
    "XANTHAANGOM (E 415)"
  ],
  "substances": [
    "HYDROXYCARBAMIDE"
  ],
  "leaflet_url": null,
  "authorised_at": "2019/07/01",
  "procedure_number": "EMEA/H/C/004837",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/19/1366",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about hydroxycarbamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console